Minutia

Minutia is a private, preclinical-stage biotech founded in 2019 and based in San Francisco, focused on a transformative cell therapy for diabetes. The company is developing an implantable device containing insulin-producing cells equipped with nanosensors, designed to provide both therapeutic function and real-time monitoring of graft health and performance. It has secured significant non-dilutive funding from prestigious organizations like CIRM, NIH, and JDRF, and is led by CEO Katy Digovich with industry veteran Dan Bradbury as Chairman. Minutia's approach seeks to address key limitations in current islet cell transplantation, such as graft failure and the need for invasive monitoring.

Integrated platform combining stem cell-derived insulin-producing cells with embedded nanosensors for real-time, in vivo monitoring of transplant function and health.

Minutia operates in the competitive diabetes cell therapy space, directly competing with programs like Vertex Pharmaceuticals' VX-880 (allogeneic stem cell-derived islet cells), which is already in Phase 1/2 trials. Other competitors include Sernova (cell pouch device) and CRISPR Therapeutics (gene-edited cells). Minutia's key differentiator is its integrated real-time monitoring capability, which, if proven, could address a major clinical drawback of current approaches: the inability to monitor graft health without invasive procedures.